Compare ARK Genomic Revolution ETF (ARKG) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Toronto-Dominion Bank — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Toronto-Dominion Bank trades at $120.25 (market cap $198.82B). The key difference: Toronto-Dominion Bank pays a 2.69% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | TD | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $122.25 |
52-Week Low | $23.09 | $72.55 |
Market Cap | — | $198.82B |
Dividend Yield | — | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
TD stock trades at $120.53, up 0.65% with a bullish technical signal and strong analyst consensus. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $1.71. Revenue grew to $61.28B in 2025 with a robust 23.38% net income margin, though cash flow from operations was negative. The stock trades at a P/E of 20.08 and P/B of 2.51, with a consensus price target of $153.00 representing 27% upside potential.
TD presents a compelling investment case with strong profitability metrics, consistent earnings beats, and positive analyst sentiment. Key risks include volatile operating cash flows, rising debt-to-asset ratios, and economic sensitivity. The current valuation appears reasonable relative to growth prospects, supported by institutional confidence and dividend stability. Upside potential exists if the company maintains its earnings momentum and executes on operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
